Nevro (NVRO) is a successful younger (IPO in 2014) company battling to establish its neuromodulation therapy to prevent a variety of chronic pain situations. It is working diligently to find itself as it faces the prospect of slowing growth. This article will describe the company's process and its prospects.
High-tech pain relief device powers a stock market darling until a reckoning spoils the party.
On its website, Nevro graphically describes its sinuous development path, beginning with its formation in 2006. The company follows through with commercial establishment of its pain relief